71%
of participants with major depression showed a ≥50% symptom reduction at week 4 after two psilocybin sessions.
Randomized trial · JAMA Psychiatry 5
The contemporary field was established by Roland R. Griffiths and his team at Johns Hopkins University, whose landmark 2006 study demonstrated that a single supervised psilocybin session can produce sustained, personally meaningful change — and whose 2016 randomized trial showed substantial reductions in depression and anxiety lasting at least six months.1,3 Since then, results have been replicated and extended by independent groups and published in the world's leading medical journals. The evidence below is organized the way our protocol is: Approach A — the compounds; Approach B — the sound.
Evidence strength varies by condition: depression and alcohol dependence now rest on randomized controlled trials; PTSD and OCD are supported by earlier-stage and mechanistic research.11,12 We present the science as it is — promising, rigorous, and still being written.
Auditory interventions are non-invasive, drug-free, and supported by meta-analysis and randomized trials for anxiety and pain, with Cochrane-level evidence for music therapy in depression.16,19 In compound-assisted sessions, sound is a documented driver of outcomes — which is precisely why it is a formal half of our protocol, not an afterthought.20
Why can a single session loosen patterns that years of conventional treatment could not? A leading theoretical answer is entropy — the richness and unpredictability of the brain's moment-to-moment activity. In depression, OCD, addiction and PTSD, brain dynamics become over-ordered: the same networks fire in the same loops, and experience narrows into rigid, repetitive patterns. The entropic-brain hypothesis, introduced by Robin Carhart-Harris and colleagues in 2014, proposes that tryptamine compounds push the brain into a state of elevated entropy — measurably more diverse, less predictable activity — in which rigid patterns temporarily dissolve and new configurations become possible.22 This is not metaphor: neuroimaging shows that psilocybin measurably expands the repertoire of dynamical states the brain can occupy,23 and the entropic-brain framework links exactly this increase in diversity to the lasting psychological change observed in clinical trials.22
Within this model, our working hypothesis for the sound protocol follows naturally: rhythmic auditory input does not raise entropy globally — it introduces structured variability, helping the system explore new states while keeping a coherent thread through the session. Approach A opens the window; Approach B shapes what happens inside it. This framing guides how we design, time, and measure every session at Eleusis.
Roughly 1 in 4 people treated for cancer develop clinically significant depression; in palliative-care settings, mood and adjustment disorders affect nearly 2 in 5.24 Standard antidepressants take weeks these patients may not have — and layer onto already complex medication regimens.
It is also the population where the modern evidence is most striking: in two independent randomized controlled trials — at Johns Hopkins and NYU — a single supervised psilocybin session produced rapid and sustained relief of depression and anxiety in patients with life-threatening cancer. In the Hopkins trial, about 80% of participants remained clinically improved six months later.3,4
Every statistic and statement on this site is anchored to an independent, peer-reviewed publication. The numbered citations on this page link to the full entries below.